However, a retrospective analysis of the CHRYSALIS and ADMIRAL studies demonstrated that previous treatment with FLT3 inhibitors does not affect remission rates in patients with R/R FLT3mut+ AML [36]. This evidence concerns the gene FLT3 and acute myeloid leukemia.